Keros Therapeutics, Inc. (KROS)

NASDAQ: KROS · Real-Time Price · USD

14.21

-0.21 (-1.46%)

At close: Apr 25, 2025, 4:00 PM

14.15

-0.06 (-0.42%)

Pre-market: Apr 28, 2025, 7:44 AM EDT

Keros Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-187.35	-152.99	-104.68	-58.74	-45.36	Upgrade
Depreciation & Amortization	1.23	0.82	0.67	0.38	0.28	Upgrade
Loss (Gain) From Sale of Assets	-	0	0.01	0.05	-	Upgrade
Stock-Based Compensation	34.87	28.76	18.68	11.72	4.1	Upgrade
Other Operating Activities	1.82	1.55	0.94	0.52	1.82	Upgrade
Change in Accounts Receivable	-2.6	-0.14	18	-18	-	Upgrade
Change in Accounts Payable	-0.25	1.61	-0.41	1.49	0.06	Upgrade
Change in Other Net Operating Assets	-8.59	-4.12	-3.28	0.45	2.21	Upgrade
Operating Cash Flow	-160.87	-124.51	-70.06	-62.15	-36.89	Upgrade
Capital Expenditures	-1.93	-2.46	-1.24	-1.02	-0.29	Upgrade
Investing Cash Flow	-1.93	-2.46	-1.24	-1.02	-0.29	Upgrade
Issuance of Common Stock	392.28	179.05	120.4	28.55	259.94	Upgrade
Other Financing Activities	-0.45	-0.09	-0.09	-	-19.89	Upgrade
Financing Cash Flow	391.82	178.96	120.31	28.55	296.04	Upgrade
Net Cash Flow	229.02	51.98	49.01	-34.62	258.86	Upgrade
Free Cash Flow	-162.8	-126.97	-71.3	-63.17	-37.19	Upgrade
Free Cash Flow Margin	-4585.91%	-84087.42%	-	-314.29%	-	Upgrade
Free Cash Flow Per Share	-4.35	-4.31	-2.83	-2.71	-2.40	Upgrade
Levered Free Cash Flow	-108.31	-81.25	-33.84	-39.48	-22.38	Upgrade
Unlevered Free Cash Flow	-108.31	-81.25	-33.84	-39.48	-22.37	Upgrade
Change in Net Working Capital	10.71	2.15	-19.79	15.33	-2.71	Upgrade

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q